

Report

From pandemic Covid-19 to endemic Sars-2 Omicron Disease: is Long Covid still an issue?

Carolina Diamandis, Olga Ivanova, Adrian Tudor

Corresponding Author

LCG Research
Team of Dr. Carolina Diamandis
Dr. Adrian Tudor
16 Kifissias Avenue
115 26 Athens, Hellenic Republic
www.your-doctor.com

Abstract

For many patients with severe Covid-19 disease of the pre-Omicron era, recovery is far from over with the end of acute symptoms. The authors of this paper have reviewed the currently available studies and conclude that Long-Covid appears to be a serious, sometimes even life-threatening syndrome. However, it seems to have good prospects for full recovery with multidisciplinary and evidence-based post-treatment care, which is, however, still lacking in Europe and North America. The Omicron variant appears to be a game changer in this regard as well. So far it seems that Long Covid is no common consequence of Sars-2-Omicron Disease.

Data

An analysis of electronic medical records² shows that the risk of re-hospitalization or death is significantly increased in the first year after overcoming acute symptoms of pre-Omicron Covid-19 disease, particularly from embolism and stroke. According to a study in the American Medical Journal³, intensive care patients in particular suffer from the below listed sequelae:^{2,3,4,5}

It is known from influenza and numerous other pathogens that many patients recover slowly after a supposed recovery or the end of hospitalization and are susceptible to other illnesses in the months that follow. British scientists have now examined the impact of pre-Omicron Covid-19 on health in the first year after acute symptoms ended.^{4,5}

To do so, they evaluated the contents of the OpenSAFELY database, which has access to just over one-third of the medical records of the population in the United Kingdom of Great Britain and Northern Ireland. This included approximately 25,000 patients who had been hospitalized for a pre-Omicron variant of Covid-19 in 2020 and were still alive one week after discharge. The epidemiologists first compared the data with a 5-fold larger group of adults of the same age and gender who did not have pre-Omicron Covid-19. A second group consisted of about 16,000 patients who had been hospitalized for symptomatic influenza from 2017 to 2019.

The pre-Omicron Covid-19 patients had a 2-fold increased risk of being hospitalized again or dying in the first year after hospital discharge. Bhaskaran determined an adjusted hazard ratio aHR of 2.22, which was significant with a 95% confidence interval of 2.14 to 2.30. This took into account that pre-Omicron Covid-19 patients were more likely to have comorbidities, be overweight or obese, and belong to ethnic minorities in which the risk of disease is higher.

The risk of death compared with healthy controls was increased by almost a factor of 5 (aHR 4.82; 4.48-5.19). The risk of death was also increased compared with influenza patients (aHR 1.74; 1.61 to 1.88). The endpoint of hospitalization or death occurred slightly less frequently in pre-Omicron Covid-19 patients than in influenza patients (aHR 0.95; 0.91-0.98). Among the sequelae that required hospitalization or resulted in death were lower respiratory tract infections (aHR vs healthy 8.47; 7.66-9.37), other respiratory diseases (aHR 4.28; 3.70-4.95), and mental or cognitive disorders (aHR 3.84; 2.97-4.96). The latter include dementias, which are much more common after pre-Omicron Covid-19 than after influenza (aHR 2.32; 1.48-3.64).

Recovery is particularly difficult for patients who have been treated in an intensive care unit. In a survey in the Netherlands as part of the MONITOR-IC study at 11 hospitals in the Netherlands, no fewer than 74% of those affected still reported relevant physical symptoms one year after discharge. Psychological complaints were present in 26%, and cognitive problems were experienced by 16%.

The most common somatic symptoms were a weakened physical condition (39%), joint stiffness (26%), joint pain (2%), muscle weakness (25%), and muscle pain (21%),

before shortness of breath (21%) and sensory disturbances in the limbs (21%). Among psychological effects, anxiety (18%) and depression (18%) were prominent. Overall, nearly 10% suffered from symptoms of post-traumatic stress disorder one year after hospital discharge.

Discussion

As alarming as the Long Covid⁴⁸ numbers might appear, these data lack meaningful comparative collectives. For example, it remains unclear whether endemic human coronaviruses (hCoVs), which are responsible for about one-third of all viral pneumonias in winter, produce such effects as well.^{13,14,15,16,42,48,49,50,51} The endemic hCoVs are scientific orphans, accepted as a given even though they have a much higher case fatality ratio (CFR) than seasonal influenza (influenza pandemics aside) and even Sars-2-Omicron.⁶

Epstein-Barr virus (EBV) is also notorious for its sometimes aggressive clinical course and a long time to complete recovery, as are many other viral infections.^{43,44,45} Therefore, from our point of view, a reasonable assessment of the clinical significance of Long Covid is not yet possible today. However, we assume that Sars-CoV-2 does not cause a never-ending Long Covid. This would be an unlikely feature of a virus leading to the resolution of an initial acute phase. Our observation as treating physicians is an increase in emboli and strokes after pre-Omicron Covid-19 infections as well as after vaccinations leading to the production of the Sars-CoV-2 spike protein (vector and mRNA). This risk seems to remain elevated for the unforeseeable future.⁵²

Pre-Omicron Covid-19, contrary to the legend of Covid as a primary pneumonia (and other distorted data) spread from the Communist Mainland of China, was never a primary pneumonia but a systemic endotheliitis leading to an organizing pneumonia by leaky capillaries (highly simplified).^{46,47} We saw most early deaths (day one to seven) due to thromboses and thus also in the form of ischemic stroke and pulmonary embolism. Those who died from pulmonary and multi-organ failure were those in whom, usually between days seven and ten of illness, instead of a recovering, a cytokine/bradykinin storm set in, organizing pneumonia escalated, and patients eventually died from (multi-)organ failure.^{46,47,52}

Only with the emergence of the Omicron variant did the systemic endotheliitis disease "Covid-19" finally become an (upper) respiratory tract illness with few outliers in terms of more severe courses.¹ To what extent the blood coagulation system is influenced by Sars-2-Omicron can not yet be conclusively assessed at this time. However, our impression as active bedside physicians is that the problem of embolisms/thromboses is either massively reduced with Omicron or is not longer significant. However, to be on the safe side, we continue to administer aspirin or clopidogrel to our patients for a few weeks or many months (dependent on the age and other parameters) after a Sars-2-Omicron disease; even now after the transition to the endemic phase, until it is understood to what extent Omicron is causing inflammatory changes in the vessel walls or if it is affecting the coagulation system. However, with a CFR of 0.4%, we assume that Omicron is, in fact, a hCoV-like

respiratory disease rather than a systemic syndrome.⁶ In this respect, we expect that the problem of serious Long Covid cases will not arise with Omicron and its future sub-variants. There may be isolated cases, but with the jump from Sars-CoV-2 Delta to Sars-CoV-2 Omicron, the virus has changed clinically so profoundly that for Omicron the endemic hCoVs are likely to be more appropriate points of reference than the pandemic Sars-CoV-2 virus. That the full impact of Sars-2-Omicron has not yet been sufficiently understood by colleagues who are doing research only is not surprising. The disease caused by Sars-2-Omicron is so drastically different to pre-Omicron Covid-19 that the scientific community was caught off guard by it and will need some time to integrate the data from clinical reality into their research work in the laboratories.

Conclusion

Patients who had pre-Omicron Covid-19 are indeed at a significantly elevated risk for slow recovery. Most importantly, there is an increased risk of life-threatening thromboses for weeks to many months (possibly even years), which must be curbed by appropriate drug protection, especially in patients >40 years of age and those with preexisting conditions. At the same time, this risk is presumably significantly lower with Omicron, since it appears to actually be most likely an hCoV disease of the upper respiratory tract. In perspective, this raises the question of whether the name "Covid-19" is still appropriate for the disease caused by the Sars-CoV-2 Omicron variant. We, therefore, propose to use the terms "Sars-2-Omicron Disease" or "Sars-2-Omicron" until an official new name will be introduced.

Conflicts of interest

none

References

1. Tudor, Adrian, Feldman, Jonathan, Ivanova, Olga, & Diamandis, Carolina. (2022). How the Covid-19 pandemic will end in 2022 and why we still need adapted vaccines. <https://doi.org/10.5281/zenodo.5851019>
2. Bhaskaran K, Rentsch CT, Hickman G, et al. (2022) Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. *PLoS Med.* 2022 Jan 25;19(1):e1003871. doi: 10.1371/journal.pmed.1003871. PMID: 35077449; PMCID: PMC8789178.
3. Heesakkers H, van der Hoeven JG, Corsten S et al. (2022) Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19. *JAMA.* 2022 Jan 24. doi: 10.1001/jama.2022.0040. Epub ahead of print. PMID: 35072716.

4. Williamson EJ, Walker AJ, Bhaskaran K (2020) Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8. PMID: 32640463; PMCID: PMC7611074.
5. Bhaskaran K, Rentsch CT, Hickman G et al. (2022) Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. *PLoS Med*. 2022 Jan 25;19(1):e1003871. doi: 10.1371/journal.pmed.1003871. PMID: 35077449; PMCID: PMC8789178.
6. Diamandis, Carolina, Tudor, Adrian, & Ivanova, Olga. (2022). Is Sars-CoV-2 variant Omicron less dangerous than the endemic seasonal human coronaviruses?. <https://doi.org/10.5281/zenodo.5912021>
7. Burki TK. Omicron variant and booster COVID-19 vaccines. *Lancet Respir Med*. 2021 Dec 17:S2213-2600(21)00559-2. doi: 10.1016/S2213-2600(21)00559-2. Epub ahead of print. PMID: 34929158; PMCID: PMC8683118.
8. Venkatakrishnan, A., Anand, P., Lenehan, P., Suratekar, R., Raghunathan, B., Niesen, M. J., & Soundararajan, V. (2021, December 3). Omicron variant of SARS-CoV-2 harbors a unique insertion mutation of putative viral or human genomic origin. <https://doi.org/10.31219/osf.io/f7txy>
9. Khan K, Karim F, Cele S, San JE, Lustig G, Tegally H, Bernstein M, Ganga Y, Jule Z, Reedoy K, Ngcobo N, Mazibuko M, Mthabela N, Mhlane Z, Mbatha N, Giandhari J, Ramphal Y, Naidoo T, Manickchand N, Magula N, Abdool Karim SS, Gray G, Hanekom W, von Gottberg A; COMMIT-KZN Team, Gosnell BI, Lessells RJ, Moore PL, de Oliveira T, Moosa MS, Sigal A. Omicron infection enhances neutralizing immunity against the Delta variant. *medRxiv* [Preprint]. 2021 Dec 27:2021.12.27.21268439. doi: 10.1101/2021.12.27.21268439. PMID: 34981076; PMCID: PMC8722619.
10. Christie Aschwanden (2021) Five reasons why COVID herd immunity is probably impossible. *Nature* 591, 520-522 doi: <https://doi.org/10.1038/d41586-021-00728-2>
11. Fung TS, Liu DX. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. *Annu Rev Microbiol*. 2021 Oct 8;75:19-47. PMID: 33492978.
12. Henning G et al. (2021) Preprint, mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. doi: <https://doi.org/10.1101/2021.12.14.21267769>
13. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology*. 2018 Feb;23(2):130-137. doi: 10.1111/resp.13196. Epub 2017 Oct 20. PMID: 29052924; PMCID: PMC7169239.
14. Patrick DM, Petric M, Skowronski DM, Guasparini R, Booth TF, Krajden M, McGeer P, Bastien N, Gustafson L, Dubord J, Macdonald D, David ST, Srouf LF, Parker R, Andonov A, Isaac-Renton J, Loewen N, McNabb G, McNabb A, Goh SH, Henwick S, Astell C, Guo JP, Drebot M, Tellier R, Plummer F, Brunham RC. An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus. *Can J Infect Dis Med Microbiol*. 2006 Nov;17(6):330-6. doi: 10.1155/2006/152612. PMID: 18382647

15. Choi, Wl., Kim, I.B., Park, S.J. et al. (2021) Comparison of the clinical characteristics and mortality of adults infected with human coronaviruses 229E and OC43. *Sci Rep* 11, 4499, <https://doi.org/10.1038/s41598-021-83987-3>
16. Leen Vijgen, Els Keyaerts, Elien Moës, Inge Thoelen, Elke Wollants, Philippe Lemey, Anne- Mieke Vandamme, and Marc Van Ranst (2005) Complete Genomic Sequence of Human Coronavirus OC43: Molecular Clock Analysis Suggests a Relatively Recent Zoonotic Coronavirus Transmission Event. *American Society for Microbiology. Journal of Virology* Volume 79, Issue 3, 1 February 2005, Pages 1595-1604. doi.org/10.1128/JVI.79.3.1595-1604.2005
17. Brüssow H, Brüssow L. Clinical evidence that the pandemic from 1889 to 1891 commonly called the Russian flu might have been an earlier coronavirus pandemic. *Microb Biotechnol.* 2021 Sep;14(5):1860-1870. doi: 10.1111/1751-7915.13889. Epub 2021 Jul 13. PMID: 34254725; PMCID: PMC8441924.
18. Gruber MF on behalf of the Food and Drug Administration, FDA, 2021, Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum. [https:// www.fda.gov/media/144416/download](https://www.fda.gov/media/144416/download)
19. Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. *BMJ.* 2021 Nov 29;375:n2943. doi: 10.1136/ bmj.n2943. PMID: 34845008.
20. Khan Burki T (2021) Omicron variant and booster COVID-19 vaccines. *Lancet Respir.* [doi.org/10.1016/S2213-2600\(21\)00559-2](https://doi.org/10.1016/S2213-2600(21)00559-2)
21. Tang S, Mao Y, Jones RM, Tan Q, Ji JS, Li N, Shen J, Lv Y, Pan L, Ding P, Wang X, Wang Y, MacIntyre CR, Shi X. Aerosol transmission of SARS-CoV-2? Evidence, prevention and control. *Environ Int.* 2020 Nov;144:106039. doi: 10.1016/j.envint.2020.106039. Epub 2020 Aug 7. PMID: 32822927; PMCID: PMC7413047
22. Pragya D Yadav, Gajanan Sapkal, Rima R Sahay, Varsha Potdar, Gururaj Deshpande, Deepak Y Patil, Dimpal A Nyayanit, Anita M Shete, Jayanthi Shastri, Pradeep Awate, Bharti Malhotra, Priya Abraham (2022) Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concerns. *bioRxiv* 2022.01.24.477043; doi: <https://doi.org/10.1101/2022.01.24.477043>
23. Joseph A. Lewnard, Vennis X. Hong, Manish M. Patel, Rebecca Kahn, Marc Lipsitch, Sara Y. Tartof (2022) Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. doi: <https://doi.org/10.1101/2022.01.11.22269045>
24. Walensky, Rochelle (CDC Director), Jan 12th 2022 on twitter messenger service.
25. Yanis Roussela Audrey Giraud-Gatineau, Marie-Thérèse Jimeno, et al. (2020) SARS-CoV-2: fear versus data. *International Journal of Antimicrobial Agents.* <https://doi.org/10.1016/j.ijantimicag.2020.105947>
26. Hand J, Rose EB, Salinas A, et al. Severe respiratory illness outbreak associated with human coronavirus NL63 in a long-term care facility. *Emerg Infect Dis* 2018;24:1964–6.
27. Vandroux D, Allou N, Jabot J, et al. Intensive care admission for coronavirus OC43 respiratory tract infections. *Med Mal Infect* 2018;48:141–4.
28. Kanwar A, Selvaraju S, Esper F. Human coronavirus-HKU1 infection among adults in Cleveland, Ohio. *Open Forum Infect Dis* 2017;4 ofx052.

29. Trombetta H, Faggion HZ, Leotte J, Nogueira MB, Vidal LR, Raboni SM. Human coronavirus and severe acute respiratory infection in Southern Brazil. *Pathog Glob Health* 2016;110:113–18.
30. Lau SK, Woo PC, Yip CC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. *J Clin Microbiol* 2006;44:2063–71.
31. Owusu M, Annan A, Corman VM, et al. Human coronaviruses associated with upper respiratory tract infections in three rural areas of Ghana. *PLoS One* 2014;9:e99782.
32. Zhang SF, Tuo JL, Huang XB, et al. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010–2015 in Guangzhou. *PLoS One* 2018;13:e0191789.
33. Zeng ZQ, Chen DH, Tan WP, et al. Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China. *Eur J Clin Microbiol Infect Dis* 2018;37:363–9.
34. Sipulwa LA, Ongus JR, Coldren RL, Bulimo WD. Molecular characterization of human coronaviruses and their circulation dynamics in Kenya, 2009–2012. *Virol J* 2016;13:18.
35. Kiyuka PK, Agoti CN, Munywoki PK, et al. Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya. *J Infect Dis* 2018;217:1728–39.
36. Killerby ME, Biggs HM, Haynes A, et al. Human coronavirus circulation in the United States 2014–2017. *J Clin Virol* 2018;101:52–6.
37. Choi, WI., Kim, I.B., Park, S.J. *et al.* Comparison of the clinical characteristics and mortality of adults infected with human coronaviruses 229E and OC43. *Sci Rep* 11, 4499 (2021). <https://doi.org/10.1038/s41598-021-83987-3>
38. Jain S, Self WH, Wunderink RG; CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization. *N Engl J Med*. 2015 Dec 10;373(24):2382. doi: 10.1056/NEJMc1511751. PMID: 26650159.
39. Rao, Suchitraa; Nyquist, Ann-Christinea (2014) Respiratory viruses and their impact in healthcare, *Current Opinion in Infectious Diseases*: August 2014 - Volume 27 - Issue 4 - p 342-347, doi: 10.1097/QCO.0000000000000079
40. Julian W Tang, Tommy T Lam, Hassan Zaraket, et al. (2017) Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance. *The Lancet Infect Dis*, doi.org/10.1016/S1473-3099(17)30238-4
41. Walsh EE, Shin JH, Falsey AR. Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations. *J Infect Dis*. 2013 Nov 15;208(10):1634-42. doi: 10.1093/infdis/jit393. Epub 2013 Aug 6. PMID: 23922367; PMCID: PMC3805243.
42. Shirato K, Imada Y, Kawase M, Nakagaki K, Matsuyama S, Taguchi F. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. *J Med Virol*. 2014 Dec;86(12):2146-53. doi: 10.1002/jmv.23950. Epub 2014 Apr 24. PMID: 24760654; PMCID: PMC7166330.
43. Rezk SA, Zhao X, Weiss LM (September 2018). "Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update". *Human Pathology*. 79: 18–41. doi:10.1016/j.humpath.2018.05.020. PMID 29885408. S2CID 47010934.

44. Amon W, Farrell PJ (2004). Reactivation of Epstein-Barr virus from latency. *Reviews in Medical Virology*. 15 (3): 149–56. doi:10.1002/rmv.456. PMID 15546128
45. ACP (1993) Epstein–Barr Virus Infections: Biology, Pathogenesis, and Management. *Annals of Internal Medicine*. ACP. 118 (1): 45–58. doi:10.7326/0003-4819-118-1-199301010-00009. PMID 8380053
46. Oikonomou, A; Hansell, DM (2001). "Organizing pneumonia: the many morphological faces". *European Radiology*. 12 (6): 1486–96. doi:10.1007/s00330-001-1211-3. PMID 12042959
47. Kory, Pierre; Kanne, Jeffrey P (2020-09-22). "SARS-CoV-2 organizing pneumonia:'Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?'". *BMJ*. 7 (1): e000724. doi:10.1136/bmjresp-2020-000724. PMC 7509945. PMID 32963028
48. Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. *Crit Rev Clin Lab Sci*. 2021 Aug;58(5):297-310. doi: 10.1080/10408363.2020.1860895. Epub 2020 Dec 21. PMID: 33347790.
49. Halpin S, O'Connor R, Sivan M. Long COVID and chronic COVID syndromes. *J Med Virol*. 2021 Mar;93(3):1242-1243. doi: 10.1002/jmv.26587. Epub 2020 Oct 30. PMID: 33034893; PMCID: PMC7675759.
50. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. *BMJ*. 2021 Jul 26;374:n1648. doi: 10.1136/bmj.n1648. Erratum in: *BMJ*. 2021 Aug 3;374:n1944. PMID: 34312178.
51. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. *Infect Dis (Lond)*. 2021 Oct;53(10):737-754. doi: 10.1080/23744235.2021.1924397. Epub 2021 May 22. PMID: 34024217; PMCID: PMC8146298.
52. Clinical raw data, not published yet.

Science. Proudly made in Greece.

